Together with the effect of Piceatannol on cell migration (Fig 4B), our data demonstrate that compounds that target Syk catalytic activity are less efficient than compound C-13 on the inhibition of CRC cell lines proliferation and motility. The gene discussed is SYK; the disease is colorectal carcinoma.